Ethical Issues of Sequencing Babies at Birth
News Mar 28, 2018 | Original story from the Nuffield Council on Bioethics
The Nuffield Council on Bioethics has today published a briefing note that examines the ethical issues raised by whole genome sequencing of babies.
Whole genome sequencing is starting to be used in the NHS in the care of seriously ill babies, and could also become available to parents through commercial companies in future. The technology has the potential to reveal large amounts of genetic information about the baby, raising questions about how this information will be interpreted, shared with parents, stored and used by others.
Whole genome sequencing using a blood or saliva sample is now cheaper and faster than ever before. It usually takes around four weeks and costs around £1,000. However, interpreting the results remains difficult, time-consuming, and expensive.
Why sequence the genome of babies?
Whole genome sequencing can help to diagnose a seriously ill baby with a suspected genetic disease, or to predict how a baby will respond to medicines. It could also be used to predict a baby’s chance of developing disease in childhood or adulthood, to find out about genetic factors that could affect future siblings, and to contribute to research databases to help better understand genetic disease. However, the significance of large amounts of the genetic code is currently unknown.
Whole genome sequencing is not yet widely available in the NHS, but that is likely to change with advances in genomic medicine, for example with the completion later this year of the UK’s 100,000 Genomes Project. Some suggest that the NHS newborn screening programme should be expanded to include more childhood conditions, and that using whole genome sequencing could become a cost effective way to achieve this.
In the commercial sector, whole genome sequencing is already available to adults through several US companies. Some companies offer or are planning to offer newborn screening tests that search for large numbers of genetic conditions.
Whole genome sequencing of babies raises important questions about what kind of genetic information should be shared with parents, how parents can be supported to make informed choices, and how genomic information should be stored and accessed by others, such as researchers. There are also broader questions about whether increased uptake of whole genome sequencing will change views about genetic variation and disability in society.
The briefing note concludes that:
Whole genome and exome sequencing has the potential to improve the care and treatment of seriously ill babies.
The consequences of sharing any additional findings with parents are not yet known, and how genomic data should be stored, accessed, and used requires further public consideration.
There is ongoing debate about whether genome sequencing could be used to expand NHS newborn screening to include more specific genetic conditions, and how the benefits and harms of screening programmes should be weighed.
Within the medical genetics community, using whole genome sequencing to look opportunistically for a broad range of conditions and traits in babies who are not ill is widely thought to be unacceptable. However, some parents want to receive a broad range of health-related results from whole genome sequencing and might be able to access such results from commercial companies in future.
Professor Dave Archard, Chair of the Nuffield Council on Bioethics says: “Genome sequencing technology has moved at an incredible pace, and we are starting to see the benefits that it can offer to patients with genetic disease. But we need to think carefully about how we handle the sensitive information that can be revealed. Babies do not get a say in this, making it especially important that they, and others, are not disadvantaged in their future lives by a decision taken at birth. We need to make sure there are opportunities for public consideration of the challenges.”
This article has been republished from materials provided by the Nuffield Council on Bioethics. Note: material may have been edited for length and content. For further information, please contact the cited source.
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018